Octreotide scan

Source: Wikipedia, the free encyclopedia.
Octreotide scan
neuroendocrine carcinoma of the mesentery. Radiotracer accumulation in the left thyroid in 10/2003 (arrow). The mesenterial neuroendocrine tumor became clearly visible in 4/2005 (arrow).
Synonymsocreoscan
ICD-9-CM92.18
OPS-301 code3-70c

An octreotide scan is a type of

tumor cells that have receptors for somatostatin (i.e. gastrinoma, glucagonoma, etc.). A gamma camera detects the radioactive octreotide, and makes pictures showing where the tumor cells are in the body, typically by a SPECT technique. A technetium-99m based radiopharmaceutical kit is also available.[2][3]

Octreotide scanning is reported to have a sensitivity between 75% and 100% for detecting pancreatic neuroendocrine tumors.[4]

Instead of gamma-emitting 111In, certain octreotide derivatives such as

copper-64 DOTATATE scans. Somatostatin receptor imaging can now be performed with positron emission tomography (PET) which offers higher resolution and more rapid imaging.[5]

Indications

An octreotide scan may be used to locate suspected primary neuroendocrine tumours (NET) or for follow-up or staging after treatment.[6][7][8]

Where indicated, octreotide scanning for NET tumors is being increasingly replaced by

copper-64 DOTATATE scans.[9]

Procedure

Indium-111

Indium In-111 pentetreotide
Clinical data
Trade namesOctreoscan
Other namesMP-1727
License data
Intravenous
ATC code
Legal status
Legal status
Identifiers
JSmol)
  • [111In+3].CC(O)C(CO)N=C(O)C1CSSCC(N=C(O)C(CC2=CC=CC=C2)N=C([O-])CN(CCN(CCC(C(O)=O)C(O)=O)CC([O-])=O)CC([O-])=O)C(O)=NC(CC2=CC=CC=C2)C(O)=NC(CC2=CNC3=CC=CC=C23)C(O)=NC(CCCCN)C([O-])=NC(C(C)O)C(O)=N1
  • InChI=1S/C62H84N12O19S2.In/c1-35(76)47(32-75)69-59(88)49-34-95-94-33-48(70-55(84)44(25-37-13-5-3-6-14-37)65-50(78)29-74(31-52(81)82)24-23-73(30-51(79)80)22-20-41(61(90)91)62(92)93)58(87)67-45(26-38-15-7-4-8-16-38)56(85)68-46(27-39-28-64-42-18-10-9-17-40(39)42)57(86)66-43(19-11-12-21-63)54(83)72-53(36(2)77)60(89)71-49;/h3-10,13-18,28,35-36,41,43-49,53,64,75-77H,11-12,19-27,29-34,63H2,1-2H3,(H,65,78)(H,66,86)(H,67,87)(H,68,85)(H,69,88)(H,70,84)(H,71,89)(H,72,83)(H,79,80)(H,81,82)(H,90,91)(H,92,93);/q;+3/p-4/i;1-4
  • Key:ZKZPXKKVDJOAIS-JWFOFJTQSA-J

The

DTPA conjugate of octreotide.[6][11]

Approximately 200

megabecquerels (MBq) of indium-111 is injected intravenously. Imaging takes place 24 hours after injection, but may also be carried out at 4 and 48 hours.[7][12]

Technetium-99m

The 99mTc product is supplied as a kit with two vials, one containing the

chelating agent ethylenediaminediacetic acid (EDDA) and the other the HYNIC-Tyr3-octreotide chelator and somatostatin analog.[13] Approximately 400-700 MBq may be administered, with imaging at 2, 4, and occasionally 24 hours post administration.[14] 99mTc based octreotide imaging shows slightly higher sensitivity than 111In.[2][15]

References

  1. ^ medicinenet.com > Carcinoid Syndrome (cont.) By Dennis Lee and Jay Marks. Retrieved Mars 2011
  2. ^
    PMID 31886756
    .
  3. S2CID 199443705
    .
  4. PMID 11965603
    .
  5. S2CID 21843609
    .
  6. ^
    S2CID 13519061
    .
  7. ^
    S2CID 398563
    .
  8. ISBN 9781441958600
    .
  9. PMID 30096273
    .
  10. ^ "Octreoscan- indium in -111 pentetreotide kit". DailyMed. Retrieved 27 December 2021.
  11. ^ "In 111 pentetreotide". NCI Drug Dictionary. National Cancer Institute. 2011-02-02. Retrieved 3 October 2017.
  12. PMID 22068564
    .
  13. ^ "TEKTROTYD". ROTOP Pharmaka. Retrieved 9 January 2022.
  14. PMID 27479887
    .
  15. ^ Federal Institute for Drugs and Medical Devices (6 May 2020). "TEKTROTYD Public Assessment Report (PAR)". Human MRIndex. Heads of Medicines Agencies. Retrieved 9 January 2022.

External links

Public Domain This article incorporates

U.S. National Cancer Institute
.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Octreotide_scan&oldid=1187886360"